{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.777","value":"53.33"},{"groupId":"OG001","spread":"12.588","value":"33.24"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"QTcF: corrected QT interval \\[QTc\\] using Fridericia's formula) and other electrocardiogram (ECG) parameters in subjects with solid tumours who have progressed after at least 1 line of therapy and for whom no other standard therapy with proven clinical benefit is available.\n\nWithin each cycle a Change from baseline (CfB) is calculated for QTcF relative to the baseline value of day 1 of the cycle. QTcF CfB= QTcF Post-dose value - QTcF pre-dose value of D1 ECG Parameters: 4-hours ECG holter monitoring in C1 and ECGs during EDO-S101 administration.\n\nContinuous variables the mean and standard deviation are presented together with the total number of observations and the number of missing and non-missing values.","dispersionType":"Standard Deviation","groups":[{"description":"6 Patients treated with 60 mg/m2 as a single agent of Tinostamustine administered over 60 minutes infusion time","id":"OG000","title":"Tinostamustine (EDO-S101) - Sub Study 1 (SS1)"},{"description":"7 Patients treated with 80 mg/m2 as a single agent of Tinostamustine administered over 80 minutes infusion time","id":"OG001","title":"Tinostamustine (EDO-S101) - Sub Study 2 (SS2)"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"From cycle 1 and at every cycle on treatment days D1 and D15, assessed pre-dose and post-start of infusion at 30 and 80mins (Substudy 2 - up to 6 months) and 30, 60, 90, 120 and 180mins (substudy 1 - up to 6 months).","title":"Highest Change From Baseline in QTcF in Sub-studies","type":"PRIMARY","unitOfMeasure":"msec"}